comprehensive -WSS

comprehensive

author：hotspot 2025-09-28 15:57:05 - browse：55421

An advisory committee to the Food and Drug Administration will convene on Tuesday to evaluate the benefits of renal denervation, a one-time surgical procedure that works to reduce blood pressure. The promise — and the potential market — is enormous, but the data on how well the procedure works remains contentious.

The committee will evaluate data from two companies vying for market approval: ReCor Medical, a startup owned by Japanese company Otsuka Medical Devices, and device giant Medtronic, both of which have made surgical systems to treat hypertension.

Data from an analysis of three randomized clinical trials of ReCor Medical’s device showed a modest decrease in blood pressure after two months compared to a control group that received a placebo procedure. Medtronic’s late-stage trial showed that renal denervation reduced hypertension when measuring blood pressure in the doctor’s office, but did not show a reduction in blood pressure when patients measured it at home over 24 hours. At-home blood pressure is considered the more accurate measure, as blood pressure levels tend to artificially rise with anxiety in the clinic. Neither study presented serious safety concerns.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： David Sabatini, ex

hotspot

WSS

Time to name cancers by genetics, not organ of origin, expert says

Congressmen charge Covid hearing ‘could have been an email’

Congressmen charge Covid hearing ‘could have been an email’

Even great ERs can’t make up for American health disparities

ARCH Venture Partners is raising $3 billion for a life sciences fund

What we need to know about Arena Bioworks

entertainment

comprehensive

focus

Affirmative action in medical school literally saved lives

Congress must reauthorize a committee to support older Americans

DIEP, the 'gold standard' of breast reconstruction, is under threat

Hospitals look to new technology to keep health care workers safe

How one medical school became remarkably diverse

In key trial, Verve's treatment lowers cholesterol levels in patients

Dobbs anniversary: the lost opportunity of abortion as health care

New Ultima Genomics DNA sequencer can read genome for $100

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

U.K. considers world's first use of meningitis vaccine to address gonorrhea

hotspot

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

Morphosys mixed study results for blood cancer drug

General Catalyst, Summa Health deal will turn on physician buy

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Congressmen charge Covid hearing ‘could have been an email’

Cybersecurity threat forces Lurie Children's to take systems offline

hotspot

explore

hotspot

hotspot